Although Redx has only been in operation since late-2010, it has already created several valuable drug candidates that are about to begin clinical development. Progress into the clinic will enhance significantly the value of these drug candidates as well as providing further technical validation of the company’s approach. Redx recently announced that its porcupine inhibitor (RXC004) has a potential role in cancer immunotherapy. Redx has now confirmed that RXC004 enhances the effect of a
05 Oct 2016
Porcupine inhibitor enhances anti-PD-1 effect
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Porcupine inhibitor enhances anti-PD-1 effect
Redx Pharma Plc (REDX:LON) | 9.0 0 (-2.7%) | Mkt Cap: 35.0m
- Published:
05 Oct 2016 -
Author:
Martin Hall -
Pages:
4
Although Redx has only been in operation since late-2010, it has already created several valuable drug candidates that are about to begin clinical development. Progress into the clinic will enhance significantly the value of these drug candidates as well as providing further technical validation of the company’s approach. Redx recently announced that its porcupine inhibitor (RXC004) has a potential role in cancer immunotherapy. Redx has now confirmed that RXC004 enhances the effect of a